A Phase 1 interventional study of cobimetinib and dextromethorphan in Solid Tumor, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment \[21/7 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
Drug: cobimetinib
Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment \[14/14 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
Drug: cobimetinib
Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment \[21/7 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
Drug: cobimetinib
Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment \[14/14 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
Drug: cobimetinib
Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
Drug: cobimetinib · Drug: dextromethorphan · Drug: midazolam
Repeating oral dose
Also known as: GDC-0973/XL518
In Stage III only: single dose of dextromethorphan
In Stage III only: single dose of midazolam
Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs)
Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the cohort review committee (CRC), was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection
Time frame: Stage 1 and 1A: Days 1 to 28 of Cycle 1
Stage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule
AEs were graded according to the NCI-CTCAE v3.0. A DLT was determined from clinical findings during the Study Treatment Period (Cycle 1, Days 1). MTD was defined as the dose at which no DLTs were observed. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection
Time frame: Stage 1: Days 1 to 28 of Cycle 1
Stage 1A: MTD of Cobimetinib in 14/14 Schedule
AEs were graded according to NCI-CTCAE v3.0. A DLT was the basis for determining MTD in Stage 1A participants. The participants of Stage 1A are dose-escalation cohorts, starting at the MTD of the 21/7 schedule, were treated on a 14/14 schedule to determine the MTD. A DLT was defined as either of the following occurring during the Study Treatment Period: Occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants to risk of irreversible medical harm; Nonhematologic toxicity: Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment; Hematologic toxicity: Grade 4 thrombocytopenia. Grade 4 neutropenia of more than 4 days' duration; Grade 4 neutropenia of any duration with fever or documented infection. AEs (Grade 3 or higher) for which a clinical cause unrelated to cobimetinib was evident was not considered DLTs.
Time frame: Stage 1A: Days 1 to 28 of Cycle 1
Stage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 1
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on Day 1, Cycle 1 in Stage 1 and was measured as nanograms per milliliter (ng/mL).
Time frame: Stage 1: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1 and pre-dose on Cycle 1 Day 2
Stage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 1
The area under the concentrations-time curve (AUC0-24) was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samples. AUC is measured as hours times nanograms per milliliter (h\*ng/mL).
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 1
Tmax is defined as the time to reach Cmax during stage 1 at Day 1 Cycle 1.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1 and pre-dose on Cycle 1 Day 2
Stage 1: Tmax of Cobimetinib at Steady State
Tmax is defined as the time to reach Cmax during stage 1 in steady state. Steady state was reached when overall intake of cobimetinib was in dynamic equilibrium with its elimination.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1: AUC 0-24 of Cobimetinib at Steady State
The area under the AUC0-24 for steady state in stage 1 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1: AUC 0-24/D of Cobimetinib at Steady State
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1: Accumulation Ratio of Cobimetinib at Steady State
Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1, Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1: Apparent Clearance of Cobimetinib at Steady State
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1: Half-Life (t1/2) of Cobimetinib at Steady State
t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1 in steady state.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1: Cmax of Cobimetinib at Steady State
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1 and was measured at steady state in ng/mL.
Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Stage 1A: Tmax of Cobimetinib at Cycle 1 Day 1
Tmax is defined as the time to reach Cmax during stage 1A at Day 1.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 1A: Cmax of Cobimetinib at Cycle 1 Day 1
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on on Day 1 in Stage 1A and was measured as ng/mL.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 1A: AUC 0-24 of Cobimetinib at Cycle 1 Day 1
AUC0-24 for stage 1A was calculated on Day 1 with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 1A: t1/2 of Cobimetinib at Steady State
t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1A in steady state.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 1A: Tmax of Cobimetinib at Steady State
Tmax is defined as the time to reach Cmax during stage 1A in steady state.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 1A: Apparent Clearance of Cobimetinib at Steady State
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 1A: Accumulation Ratio of Cobimetinib at Steady State
Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 1A: AUC 0-24 of Cobimetinib at Steady State
The area under the AUC0-24 for steady state in stage 1A was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 1A: AUC 0-24/D of Cobimetinib at Steady State
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 1A: Cmax of Cobimetinib at Steady State
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1A and was measured in steady state as ng/mL.
Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Stage 2: Cmax of Cobimetinib at Cycle 1 Day 1
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 2 and was measured in ng/mL.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 2:AUC 0-24 of Cobimetinib at Cycle 1 Day 1
The area under the AUC0-24 on Day 1 in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 2: Tmax of Cobimetinib at Cycle 1 Day 1
Tmax is defined as the time to reach Cmax during stage 2 on Day 1.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Stage 2: Tmax of Cobimetinib at Steady State
Tmax is defined as the time to reach Cmax during stage 2 in steady state.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Stage 2: AUC 0-24 of Cobimetinib at Steady State
The area under the AUC0-24 for steady state in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Stage 2: AUC 0-24/D of Cobimetinib at Steady State
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Stage 2: Accumulation Ratio of Cobimetinib at Steady State
Accumulation ratio is AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Stage 2: Apparent Clearance of Cobimetinib at Steady State
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Stage 2:Half-Life of Cobimetinib at Steady State
T1/2 half-life of cobimetinib measured over the terminal phase by noncompartmental analysis.
Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Stage 2A: AUC 0-24/D of Cobimetinib at Steady State
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Stage 2A: Accumulation Ratio of Cobimetinib at Steady State
Accumulation Ratio AUC0-24 is ratio of AUC on Day 20: Day 1.
Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Stage 2A: Apparent Clearance of Cobimetinib at Steady State
Apparent clearance is the plasma clearance of absorbed drug.
Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Stage 2A: Half-Life of Cobimetinib at Steady State
Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Stage 2A: Tmax of Cobimetinib at Steady State
Tmax is defined as the time to reach Cmax during stage 2A in steady state.
Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Stage 2A: Cmax of Cobimetinib at Steady State
Cmax is the maximum plasma concentration achieved following the Day 20 dose in Stage 2A.
Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Stage III: Cmax of Dextromethorphan
Cmax is defined as maximum observed plasma concentration and was determined both in the presence (Cycle 1 Day 15) and absence of cobimetinib (Cycle 1 Day 1).
Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Stage III: AUC 0-24 of Dextromethorphan
AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was determined both in presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Stage III: AUC 0-inf of Dextromethorphan
AUC0-inf is AUC from time 0 to infinity and was calculated both in presence Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Stage III: Cmax of Midazolam
Cmax is the maximum observed plasma concentration and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Stage III: AUC0-24 of Midazolam
AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was calculated both in the presence (Cycle 1 Day 15) and absence (CXycle 1 Day 1) of cobimetinib.
Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Stage III: AUC0-inf of Midazolam
AUC0-inf is the AUC from time 0 to infinity and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
| Milestone | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 6 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 3 | 3 | 3 | 5 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 2 | 2 | 2 | 3 | 2 | 2 | 4 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unspecified reason | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 8 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 8 | 6 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 5 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Unspecified reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Milestone | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unspecified reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 |
| Withdrew: Unspecified reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Unspecified reason | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the cohort review committee (CRC), was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection
| participants | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 2 |
AEs were graded according to the NCI-CTCAE v3.0. A DLT was determined from clinical findings during the Study Treatment Period (Cycle 1, Days 1). MTD was defined as the dose at which no DLTs were observed. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection
| milligrams (mg) | Stage 1 All Cohorts (21/7) |
|---|---|
| Stage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule | 60 |
AEs were graded according to NCI-CTCAE v3.0. A DLT was the basis for determining MTD in Stage 1A participants. The participants of Stage 1A are dose-escalation cohorts, starting at the MTD of the 21/7 schedule, were treated on a 14/14 schedule to determine the MTD. A DLT was defined as either of the following occurring during the Study Treatment Period: Occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants to risk of irreversible medical harm; Nonhematologic toxicity: Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment; Hematologic toxicity: Grade 4 thrombocytopenia. Grade 4 neutropenia of more than 4 days' duration; Grade 4 neutropenia of any duration with fever or documented infection. AEs (Grade 3 or higher) for which a clinical cause unrelated to cobimetinib was evident was not considered DLTs.
| mg | Stage 1A - All Cohorts (14/14) |
|---|---|
| Stage 1A: MTD of Cobimetinib in 14/14 Schedule | 100 |
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on Day 1, Cycle 1 in Stage 1 and was measured as nanograms per milliliter (ng/mL).
| ng/mL | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 1 | 4.51 ± 5.8 | 6.92 ± 3.8 | 18.3 ± 13.0 | 18.8 ± 5.1 | 30.8 ± 69.0 | 71.7 ± 57.0 | 163.0 ± 79.0 | 261.0 ± 110.0 |
The area under the concentrations-time curve (AUC0-24) was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samples. AUC is measured as hours times nanograms per milliliter (h\*ng/mL).
| h*ng/mL | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 1 | 56.2 ± 65.0 | 68.0 ± 47.0 | 203.0 ± 130.0 | 242.0 ± 64.0 | 440.0 ± 870.0 | 785.0 ± 560.0 | 1620.0 ± 830.0 | 3060.0 ± 950.0 |
Tmax is defined as the time to reach Cmax during stage 1 at Day 1 Cycle 1.
| hours | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 1 | 2.0 (2.0 to 8.0) | 1.0 (1.0 to 2.0) | 1.5 (1.0 to 1.5) | 3.0 (1.0 to 4.0) | 4.0 (2.0 to 4.0) | 2.5 (1.5 to 6.0) | 2.0 (1.0 to 4.0) | 2.0 (1.5 to 2.0) |
Tmax is defined as the time to reach Cmax during stage 1 in steady state. Steady state was reached when overall intake of cobimetinib was in dynamic equilibrium with its elimination.
| hours | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Tmax of Cobimetinib at Steady State | 4.0 (2.0 to 4.0) | 1.0 (1.0 to 2.0) | 2.25 (1.5 to 3.0) | 4.0 (3.0 to 4.0) | 3.0 (3.0 to 3.0) | 2.0 (1.5 to 3.0) | 3.0 (1.5 to 4.0) | 2.5 (2.0 to 4.0) |
The area under the AUC0-24 for steady state in stage 1 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
| h*ng/mL | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: AUC 0-24 of Cobimetinib at Steady State | 202.0 ± 158.0 | 288.0 ± 200.0 | 411.0 ± 199.0 | 763.0 ± 168.0 | 886.0 | 5370.0 ± 4600.0 | 6250.0 ± 3540.0 | 10500.0 ± 10500.0 |
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
| ng*hr/mL/mg | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: AUC 0-24/D of Cobimetinib at Steady State | 62.4 ± 36.3 | 34 ± 16.9 | 28.2 ± 8.43 | 76.3 ± 16.8 | 44.3 | 134 ± 115 | 104 ± 59.1 | 132 ± 131 |
Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.
| ratio | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Accumulation Ratio of Cobimetinib at Steady State | 3.56 ± 1.76 | 3.66 ± 0.901 | 2.65 ± 0.886 | 3.23 ± 1.03 | 2.96 | 3.61 ± 2.27 | 2.87 ± 0.787 | 3.26 ± 2.1 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.
| Liters per hour (L/hr) | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Apparent Clearance of Cobimetinib at Steady State | 22.4 ± 17.2 | 34.0 ± 14.2 | 37.1 ± 11.1 | 13.5 ± 2.71 | 22.6 | 14.0 ± 10.1 | 11.8 ± 5.71 | 11.6 ± 5.42 |
t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1 in steady state.
| hours | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Half-Life (t1/2) of Cobimetinib at Steady State | 80.0 (80.0 to 80.0) | 64.0 (51.5 to 73) | 47.8 (46.5 to 49.1) | 66.0 (34.0 to 67.5) | 50.5 (50.5 to 50.5) | 41.3 (34.2 to 62.4) | 51.3 (23.1 to 61.4) | 60.0 (33.5 to 65.4) |
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1 and was measured at steady state in ng/mL.
| ng/mL | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) |
|---|---|---|---|---|---|---|---|---|
| Stage 1: Cmax of Cobimetinib at Steady State | 13.5 ± 9.53 | 19.8 ± 15.2 | 28.7 ± 8.63 | 53.0 ± 5.4 | 54.7 | 341.0 ± 244.0 | 401.0 ± 214.0 | 641.0 ± 514.0 |
Tmax is defined as the time to reach Cmax during stage 1A at Day 1.
| hours | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: Tmax of Cobimetinib at Cycle 1 Day 1 | 3.0 (1.5 to 4.0) | 4.0 (2.0 to 24) | 3.5 (1.5 to 6) | 2.5 (2.0 to 4.0) |
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on on Day 1 in Stage 1A and was measured as ng/mL.
| ng/mL | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: Cmax of Cobimetinib at Cycle 1 Day 1 | 78.4 ± 88.0 | 167.0 ± 63.0 | 258.0 ± 140.0 | 533.0 ± 347.0 |
AUC0-24 for stage 1A was calculated on Day 1 with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
| h*ng/mL | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: AUC 0-24 of Cobimetinib at Cycle 1 Day 1 | 1140 ± 1150 | 2130 ± 70.1 | 4020 ± 2000 | 7190 ± 3640 |
t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1A in steady state.
| hours | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: t1/2 of Cobimetinib at Steady State | 59.4 (59.4 to 59.4) | 44.1 (44.1 to 44.1) | 51.6 (48.1 to 71.1) | 47.7 (47.7 to 47.7) |
Tmax is defined as the time to reach Cmax during stage 1A in steady state.
| hours | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: Tmax of Cobimetinib at Steady State | 2.0 (1.5 to 4.0) | 2.0 (2.0 to 6.0) | 3 (1.5 to 4.0) | 6 (2.0 to 6.0) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.
| L/hr | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: Apparent Clearance of Cobimetinib at Steady State | 25.1 ± 13.5 | 14.9 ± 8.33 | 21.9 ± 20.3 | 6.9 ± 3.22 |
Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.
| ratio | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: Accumulation Ratio of Cobimetinib at Steady State | 2.32 ± 0.448 | 3.14 ± 1.77 | 2.6 ± 2.32 | 5.15 ± 2.08 |
The area under the AUC0-24 for steady state in stage 1A was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
| h*ng/mL | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: AUC 0-24 of Cobimetinib at Steady State | 2990.0 ± 1750.0 | 6740.0 ± 3830.0 | 11500.0 ± 10500.0 | 21500.0 ± 11300.0 |
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
| ng*hr/mL/mg | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: AUC 0-24/D of Cobimetinib at Steady State | 49.8 ± 29.2 | 84.2 ± 47.8 | 115.0 ± 105.0 | 172.0 ± 90.4 |
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1A and was measured in steady state as ng/mL.
| ng/mL | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) |
|---|---|---|---|---|
| Stage 1A: Cmax of Cobimetinib at Steady State | 180.0 ± 101.0 | 494.0 ± 175.0 | 640.0 ± 511.0 | 1160.0 ± 540.0 |
Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 2 and was measured in ng/mL.
| ng/mL | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: Cmax of Cobimetinib at Cycle 1 Day 1 | 184.0 ± 160.0 |
The area under the AUC0-24 on Day 1 in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
| h*ng/mL | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2:AUC 0-24 of Cobimetinib at Cycle 1 Day 1 | 3060.0 ± 2110.0 |
Tmax is defined as the time to reach Cmax during stage 2 on Day 1.
| hours | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: Tmax of Cobimetinib at Cycle 1 Day 1 | 3.0 (1.0 to 6.0) |
Tmax is defined as the time to reach Cmax during stage 2 in steady state.
| hours | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: Tmax of Cobimetinib at Steady State | 4.0 (1.5 to 6.0) |
The area under the AUC0-24 for steady state in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.
| h*ng/mL | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: AUC 0-24 of Cobimetinib at Steady State | 10200.0 ± 5630.0 |
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
| h*ng/mL | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: AUC 0-24/D of Cobimetinib at Steady State | 102.0 ± 56.3 |
Accumulation ratio is AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.
| ratio | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: Accumulation Ratio of Cobimetinib at Steady State | 2.5 ± 0.9 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.
| L/hr | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2: Apparent Clearance of Cobimetinib at Steady State | 9.8 ± 9.9 |
T1/2 half-life of cobimetinib measured over the terminal phase by noncompartmental analysis.
| hours | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) |
|---|---|
| Stage 2:Half-Life of Cobimetinib at Steady State | 53.4 (45.3 to 68.3) |
AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.
| h*ng/mL | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) |
|---|---|
| Stage 2A: AUC 0-24/D of Cobimetinib at Steady State | 84.8 ± 52.0 |
Accumulation Ratio AUC0-24 is ratio of AUC on Day 20: Day 1.
| ratio | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) |
|---|---|
| Stage 2A: Accumulation Ratio of Cobimetinib at Steady State | 2.3 ± 1.2 |
Apparent clearance is the plasma clearance of absorbed drug.
| L/hr | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) |
|---|---|
| Stage 2A: Apparent Clearance of Cobimetinib at Steady State | 11.8 ± 5.2 |
| hours | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) |
|---|---|
| Stage 2A: Half-Life of Cobimetinib at Steady State | 42.7 (27.8 to 69.6) |
Tmax is defined as the time to reach Cmax during stage 2A in steady state.
| hours | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) |
|---|---|
| Stage 2A: Tmax of Cobimetinib at Steady State | 3.0 (1.0 to 6.0) |
Cmax is the maximum plasma concentration achieved following the Day 20 dose in Stage 2A.
| ng/mL | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) |
|---|---|
| Stage 2A: Cmax of Cobimetinib at Steady State | 315.0 ± 220.0 |
Cmax is defined as maximum observed plasma concentration and was determined both in the presence (Cycle 1 Day 15) and absence of cobimetinib (Cycle 1 Day 1).
| ng/mL | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|
| With cobimetinib - Cycle 1 Day 15(n=17) | 3.44 ± 150.0 |
| Without cobimetinib - Cycle 1 Day 1 (n=20) | 3.16 ± 273.0 |
AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was determined both in presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
| h*ng/mL | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|
| With cobimetinib - Cycle 1 Day 1 (n=17) | 24.8 ± 180.0 |
| Without cobimetinib - Cycle 1 Day1 (n=19) | 25.8 ± 240 |
AUC0-inf is AUC from time 0 to infinity and was calculated both in presence Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
| h*ng/mL | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|
| With cobimetinib - Cycle 1 Day 15 (n=13) | 29.1 ± 250.0 |
| Without cobimetinib - Cycle 1 Day1 (n=19) | 18.9 ± 124.0 |
Cmax is the maximum observed plasma concentration and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
| ng/mL | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|
| With cobimetinib - Cycle 1 Day15 (n=17) | 11.5 ± 64.0 |
| Without cobimetinib - Cycle 1 Day 1(n=20) | 10.9 ± 79.0 |
AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was calculated both in the presence (Cycle 1 Day 15) and absence (CXycle 1 Day 1) of cobimetinib.
| h*ng/mL | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|
| With cobimetinib - Cycle 1 Day 15 (n=14) | 33.0 ± 74.0 |
| Without cobimetinib - Cycle 1 Day 1 (n=11) | 33.4 ± 88.0 |
AUC0-inf is the AUC from time 0 to infinity and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.
| h*ng/mL | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|
| With cobimetinib - Cycle 1 Day 15 (n=17) | 34.9 ± 77.0 |
| Without cobimetinib Cycle 1 Day 1 (n=19) | 35.7 ± 91.0 |
Collected over AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | — | 2/4 (50%) | 4/4 (100%) |
| Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | — | 0/3 (0%) | 3/3 (100%) |
| Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | — | 1/3 (33.3%) | 3/3 (100%) |
| Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | — | 0/3 (0%) | 3/3 (100%) |
| Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | — | 1/3 (33.3%) | 3/3 (100%) |
| Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | — | 3/6 (50%) | 6/6 (100%) |
| Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | — | 3/7 (42.9%) | 7/7 (100%) |
| Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | — | 5/7 (71.4%) | 7/7 (100%) |
| Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | — | 7/21 (33.3%) | 20/21 (95.2%) |
| Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | — | 0/3 (0%) | 3/3 (100%) |
| Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | — | 1/3 (33.3%) | 3/3 (100%) |
| Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | — | 4/8 (50%) | 8/8 (100%) |
| Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | — | 3/6 (50%) | 6/6 (100%) |
| Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | — | 11/22 (50%) | 21/22 (95.5%) |
| Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan | — | 8/20 (40%) | 18/20 (90%) |
| Event | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/3 | 1/3 | 0/3 | 0/3 | 1/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 0/20 |
| Supraventricular tachycardiaCardiac disorders | 0/4 | 0/3 | 0/3 | 0/3 | 1/3 | 0/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/7 | 1/7 | 0/21 | 0/3 | 1/3 | 0/8 | 0/6 | 0/22 | 0/20 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 1/22 | 0/20 |
| Faecal incontinenceGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 1/3 | 0/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 0/20 |
| Abdominal painGastrointestinal disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 1/20 |
| IleusGastrointestinal disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 1/20 |
| Generalised oedemaGeneral disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 0/20 |
| Bile duct obstructionHepatobiliary disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 1/6 | 0/7 | 0/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 1/22 | 0/20 |
| DehydrationMetabolism and nutrition disorders | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 1/6 | 0/7 | 1/7 | 0/21 | 0/3 | 0/3 | 0/8 | 0/6 | 0/22 | 0/20 |
| Event | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/4 | 1/3 | 1/3 | 2/3 | 2/3 | 3/6 | 4/7 | 4/7 | 13/21 | 1/3 | 1/3 | 6/8 | 6/6 | 17/22 | 12/20 |
| NauseaGastrointestinal disorders | 1/4 | 0/3 | 0/3 | 2/3 | 0/3 | 1/6 | 3/7 | 3/7 | 7/21 | 0/3 | 2/3 | 6/8 | 1/6 | 9/22 | 4/20 |
| FatigueGeneral disorders | 2/4 | 2/3 | 0/3 | 2/3 | 1/3 | 2/6 | 4/7 | 3/7 | 10/21 | 0/3 | 2/3 | 6/8 | 2/6 | 14/22 | 8/20 |
| RashSkin and subcutaneous tissue disorders | 1/4 | 1/3 | 1/3 | 0/3 | 0/3 | 3/6 | 5/7 | 5/7 | 13/21 | 2/3 | 2/3 | 4/8 | 3/6 | 11/22 | 6/20 |
| Oedema peripheralGeneral disorders | 0/4 | 0/3 | 0/3 | 1/3 | 0/3 | 1/6 | 4/7 | 5/7 | 6/21 | 1/3 | 0/3 | 5/8 | 1/6 | 5/22 | 4/20 |
| VomitingGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 2/3 | 1/3 | 2/6 | 3/7 | 1/7 | 5/21 | 0/3 | 2/3 | 4/8 | 2/6 | 12/22 | 5/20 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/3 | 2/3 | 1/6 | 0/7 | 2/7 | 2/21 | 0/3 | 0/3 | 5/8 | 1/6 | 9/22 | 3/20 |
| Dry skinSkin and subcutaneous tissue disorders | 0/4 | 1/3 | 0/3 | 2/3 | 0/3 | 1/6 | 2/7 | 3/7 | 1/21 | 1/3 | 0/3 | 1/8 | 1/6 | 2/22 | 1/20 |
| PruritusSkin and subcutaneous tissue disorders | 0/4 | 2/3 | 0/3 | 0/3 | 1/3 | 1/6 | 0/7 | 1/7 | 1/21 | 0/3 | 1/3 | 1/8 | 1/6 | 1/22 | 3/20 |
| Decreased appetiteMetabolism and nutrition disorders | 1/4 | 1/3 | 0/3 | 1/3 | 0/3 | 2/6 | 0/7 | 0/7 | 5/21 | 0/3 | 2/3 | 2/8 | 0/6 | 7/22 | 6/20 |
Safety population consisted of all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.0 ± 11.52 | 60.7 ± 19.73 | 51.3 ± 6.35 | 66.0 ± 10.82 | 60.7 ± 9.61 | 62.0 ± 12.38 | 63.9 ± 5.87 | 54.4 ± 8.40 | 59.7 ± 13.08 | 52.7 ± 13.20 | 49.7 ± 21.08 | 55.1 ± 13.46 | 61.5 ± 13.61 | 61.1 ± 11.45 | 57.1 ± 15.60 | 59.1 ± 12.8 |
| Sex: Female, Male(Participants) | Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7) | Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7) | Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7) | Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7) | Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7) | Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7) | Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7) | Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7) | Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7) | Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14) | Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14) | Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14) | Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14) | Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14) | Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 0 | 2 | 3 | 1 | 3 | 2 | 3 | 11 | 1 | 3 | 4 | 4 | 10 | 9 | 59 |
| Male | 1 | 3 | 1 | 0 | 2 | 3 | 5 | 4 | 10 | 2 | 0 | 4 | 2 | 12 | 11 | 60 |
The record gives a start of May 2007, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib